AR123285A1 - Compuestos heteroarílicos sustituidos útiles como inhibidores de tlr9 - Google Patents

Compuestos heteroarílicos sustituidos útiles como inhibidores de tlr9

Info

Publication number
AR123285A1
AR123285A1 ARP210102329A ARP210102329A AR123285A1 AR 123285 A1 AR123285 A1 AR 123285A1 AR P210102329 A ARP210102329 A AR P210102329A AR P210102329 A ARP210102329 A AR P210102329A AR 123285 A1 AR123285 A1 AR 123285A1
Authority
AR
Argentina
Prior art keywords
substituted heteroaryl
compounds useful
heteroaryl compounds
tlr9 inhibitors
compounds
Prior art date
Application number
ARP210102329A
Other languages
English (en)
Inventor
Chunjian Liu
Alicia Regueiro-Ren
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR123285A1 publication Critical patent/AR123285A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describen compuestos de la fórmula (1) o una sal o profármaco del mismo, en donde X, Y, Q¹, Q², R¹, y R⁵ se definen en el presente documento. También se describen métodos para usar tales compuestos como inhibidores de TLR9 y composiciones farmacéuticas que comprenden tales compuestos. Estos compuestos son útiles para tratar, prevenir o retardar enfermedades fibróticas.
ARP210102329A 2020-08-19 2021-08-18 Compuestos heteroarílicos sustituidos útiles como inhibidores de tlr9 AR123285A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063067465P 2020-08-19 2020-08-19

Publications (1)

Publication Number Publication Date
AR123285A1 true AR123285A1 (es) 2022-11-16

Family

ID=77711459

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102329A AR123285A1 (es) 2020-08-19 2021-08-18 Compuestos heteroarílicos sustituidos útiles como inhibidores de tlr9

Country Status (13)

Country Link
US (1) US20230312565A1 (es)
EP (1) EP4200298A1 (es)
JP (1) JP2023538608A (es)
KR (1) KR20230053646A (es)
CN (1) CN115867549A (es)
AR (1) AR123285A1 (es)
AU (1) AU2021328577A1 (es)
BR (1) BR112023002646A2 (es)
CA (1) CA3189826A1 (es)
IL (1) IL300643A (es)
MX (1) MX2023001929A (es)
TW (1) TW202214233A (es)
WO (1) WO2022040267A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11807622B2 (en) 2019-01-30 2023-11-07 Insilico Medicine Ip Limited TLR 9 inhibitors
WO2023159154A1 (en) * 2022-02-18 2023-08-24 Bristol-Myers Squibb Company Substituted imidazopyridinyl compounds useful as inhibitors of tlr9
WO2024102884A1 (en) * 2022-11-10 2024-05-16 Bristol-Myers Squibb Company Substituted quinolone compounds useful as inhibitors of tlr9
WO2024102886A1 (en) * 2022-11-10 2024-05-16 Bristol-Myers Squibb Company Substituted benzimidazole compounds useful as inhibitors of tlr9

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016540013A (ja) * 2013-12-13 2016-12-22 武田薬品工業株式会社 Ｔｌｒ阻害剤としてのピロロ［３，２−ｃ］ピリジン誘導体
US11370794B2 (en) * 2016-11-11 2022-06-28 Dynavax Technologies Corporation Toll-like receptor antagonist compounds and methods of use
WO2019126082A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company 6-azaindole compounds

Also Published As

Publication number Publication date
JP2023538608A (ja) 2023-09-08
WO2022040267A1 (en) 2022-02-24
TW202214233A (zh) 2022-04-16
EP4200298A1 (en) 2023-06-28
CA3189826A1 (en) 2022-02-24
KR20230053646A (ko) 2023-04-21
IL300643A (en) 2023-04-01
MX2023001929A (es) 2023-03-09
CN115867549A (zh) 2023-03-28
BR112023002646A2 (pt) 2023-04-04
US20230312565A1 (en) 2023-10-05
AU2021328577A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
AR123284A1 (es) Compuestos heteroarílicos sustituidos útiles como inhibidores de tlr9
AR123285A1 (es) Compuestos heteroarílicos sustituidos útiles como inhibidores de tlr9
ECSP20069418A (es) Compuestos heterocíclicos como inmunomoduladores
CL2019002204A1 (es) Compuestos inhibidores del vih.
CO2022010460A2 (es) Compuestos tricíclicos sustituidos
CL2020001871A1 (es) Dihidrobenzofurano e inden analogos como inhibidores de sarcómero cardíaco.
BR112022025037A2 (pt) Compostos antivirais para tratar infecções por coronavírus, picornavírus e norovírus
PE20181045A1 (es) Compuestos utiles como inmunomoduladores
CL2017002207A1 (es) Inhibidores del factor beta de crecimiento de transformación (tgf-beta)
CO2022002804A2 (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos
AR116283A1 (es) Inhibidores del sarcómero cardíaco
AR123281A1 (es) Compuestos bicíclicos sustituidos útiles como inhibidores de tlr9
CL2020001752A1 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa.
CL2021001461A1 (es) Moduladores de trex1
DOP2021000077A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
BR112018069147A2 (pt) composto da fórmula iii, composição farmacêutica, método de inibição da função de fimh e método de tratamento de uma doença mediada por fimh
CO2023001668A2 (es) Derivados de 1h-benzo[d]imidazol como inhibidores de tlr9 para el tratamiento de fibrosis
CO2021013749A2 (es) Compuestos de aza-benzotiofeno y aza-benzofurano como antihelmínticos
CO2020005420A2 (es) Compuestos antibacterianos
CO2022012476A2 (es) Hidrato cristalino de un compuesto inhibidor de jak
DOP2021000254A (es) Compuestos de pirrolidina
DOP2019000119A (es) Moduladores de ROR gamma (RORy)
CO2023004420A2 (es) Compuestos heterocíclicos como inhibidores del bromodominio cbp/ep300
AR126251A1 (es) Inhibidores de cdk2
CL2021003139A1 (es) Compuestos tricíclicos